JP2024175003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024175003A5 JP2024175003A5 JP2024158123A JP2024158123A JP2024175003A5 JP 2024175003 A5 JP2024175003 A5 JP 2024175003A5 JP 2024158123 A JP2024158123 A JP 2024158123A JP 2024158123 A JP2024158123 A JP 2024158123A JP 2024175003 A5 JP2024175003 A5 JP 2024175003A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal
- antibody
- amino acid
- presented
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 8
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 8
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229960004669 basiliximab Drugs 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000005829 trimerization reaction Methods 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767405P | 2018-11-14 | 2018-11-14 | |
| US62/767,405 | 2018-11-14 | ||
| PCT/US2019/061552 WO2020102591A1 (en) | 2018-11-14 | 2019-11-14 | Cd25 antibodies |
| JP2021526461A JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526461A Division JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024175003A JP2024175003A (ja) | 2024-12-17 |
| JP2024175003A5 true JP2024175003A5 (enExample) | 2025-04-03 |
Family
ID=70730731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526461A Active JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
| JP2024158123A Pending JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526461A Active JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12215163B2 (enExample) |
| EP (1) | EP3880227A4 (enExample) |
| JP (2) | JP7619941B2 (enExample) |
| CN (1) | CN113677359A (enExample) |
| CA (1) | CA3120096A1 (enExample) |
| WO (1) | WO2020102591A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| CA3146394A1 (en) * | 2019-07-30 | 2021-02-04 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |
| AU2021378308A1 (en) | 2020-11-13 | 2023-06-15 | Ibio, Inc. | Cd25 antibodies |
| WO2022235295A1 (en) * | 2021-05-07 | 2022-11-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| CN115724971A (zh) * | 2021-08-09 | 2023-03-03 | 南京诺艾新生物技术有限公司 | 重组抗人cd25抗体及其应用 |
| JP2024534053A (ja) * | 2021-08-25 | 2024-09-18 | アイバイオ， インク． | 抗ｃｄ２５抗体 |
| WO2023129870A2 (en) * | 2021-12-29 | 2023-07-06 | Staidson Biopharma Inc. | ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF |
| TW202340250A (zh) * | 2022-01-17 | 2023-10-16 | 大陸商諾納生物（蘇州）有限公司 | 標靶ｃｄ２５的抗體及其製備方法和應用 |
| JP2025525430A (ja) | 2022-07-01 | 2025-08-05 | ニューロジーン・インコーポレイテッド | Ｔ制御性細胞を優先的に刺激するためのｎｅｏ－２／１５バリアント及びそれらの使用 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024213046A1 (en) * | 2023-04-11 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cd25 antibody and uses thereof |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117050165B (zh) * | 2023-08-14 | 2025-03-25 | 三优生物医药(上海)有限公司 | 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN119331099B (zh) * | 2024-11-06 | 2025-12-16 | 郑州伊美诺生物技术有限公司 | 抗嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540555A (en) * | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| BRPI0817299A8 (pt) * | 2007-09-25 | 2019-01-29 | Pastoral Greenhouse Gas Res Limited | vacinas e componentes de vacina para inibição de células microbianas |
| WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| US10544187B2 (en) * | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| WO2016179212A1 (en) * | 2015-05-05 | 2016-11-10 | Albert Einstein College Of Medicine, Inc. | Antibody therapeutics against filovirus infections and uses thereof |
| EP3538551A4 (en) | 2016-11-10 | 2020-11-11 | Fortis Therapeutics, Inc. | CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| WO2018195226A1 (en) | 2017-04-18 | 2018-10-25 | R-Pharm Overseas, Inc. | Anti-pd-l1 antibody and use thereof |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
-
2019
- 2019-11-14 EP EP19883467.3A patent/EP3880227A4/en active Pending
- 2019-11-14 CN CN201980088154.1A patent/CN113677359A/zh active Pending
- 2019-11-14 CA CA3120096A patent/CA3120096A1/en active Pending
- 2019-11-14 JP JP2021526461A patent/JP7619941B2/ja active Active
- 2019-11-14 WO PCT/US2019/061552 patent/WO2020102591A1/en not_active Ceased
-
2021
- 2021-05-13 US US17/320,125 patent/US12215163B2/en active Active
-
2024
- 2024-09-12 JP JP2024158123A patent/JP2024175003A/ja active Pending
- 2024-12-04 US US18/968,640 patent/US20250122301A1/en active Pending